We recently published 10 Double-Digit Winners You Wish You Bought Yesterday. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is ...

Sarepta Therapeutics is selling off Arrowhead Pharmaceuticals shares to stretch its cash runway while also inking a share ...

Sarepta Therapeutics Inc. landed a deal with investors to restructure around $700 million of debt, giving the company a ...

Sarepta is facing a number of issues currently, including platform-level safety concerns, management credibility issues, etc.

A refinancing deal will delay the maturity of $700 million in debt until 2030, allowing the company to “fully fund” its ...

Sarepta’s troubles had nothing to do with Arrowhead’s assets, and yet both companies have seen their stock prices decline ...

Arrowhead Pharmaceuticals has a market capitalization of US$6.9b, so it's too big to fly under the radar. We'd expect to see both institutions and retail investors owning a portion of the company.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 third quarter ended June 30, 2025. The Company is hosting a conference call today, August 7, 2025, ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) shareholders might be concerned after seeing the share price drop 12% in the last month.

Last month, shares of Arrowhead Pharmaceuticals (NASDAQ: ARWR) saw a year to date growth in their share price of over 400%, increasing from $3.70 at the start of January to more than $19.00 at the ...

Source: Arrowhead Pharmaceuticals, Inc. Arrowhead Pharmaceuticals, Inc. Vince Anzalone, CFA 626-304-3400 [email protected] Investors: LifeSci Advisors, LLC Brian Ritchie 212-915-2578 ...

What happenedShares of Arrowhead Pharmaceuticals (NASDAQ: ARWR) are getting pummeled in response to bad news for the company's experimental cystic fibrosis therapy. Investors unhappy about a ...